DALAZATIDE, AN INHIBITOR OF THE KV1.3 CHANNEL ON ACTIVATED EFFECTOR MEMORY T CELLS, HAS IMMUNOTHERAPY POTENTIAL IN SYSTEMIC LUPUS ERYTHEMATOSUS

被引：1
|
作者：
Stevens, A. M. [1 ,2 ]
Yuasa, M. [2 ]
Peckham, D. [3 ]
Olsen, C.
Iadonato, S. P. [3 ,4 ]
Probst, P. [3 ]
机构：
[1] Univ Washington, Pediatr, Seattle, WA 98195 USA
[2] Seattle Childrens Res Inst, Ctr Immun & Immunotherapies, Seattle, WA USA
[3] Kineta Inc, Seattle, WA USA
[4] KPI Therapeut Inc, Seattle, WA USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2016年 / 75卷
关键词：
D O I：
10.1136/annrheumdis-2016-eular.5866
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
THU0285
引用
收藏
页码：290 / 290
页数：1
相关论文
共 50 条
  • [31] Dopamine exerts no acute effects on Kv1.3 in activated encephalitogenic T cells
    Strauss, U
    Herbrik, M
    Mix, E
    Bajorat, R
    Jung, S
    Gimsa, U
    Rolfs, A
    NEUROIMMUNOMODULATION, 2005, 12 (01) : 45 - 53
  • [32] Kv1.3 blockers ameliorate allergic contact dermatitis by preferentially suppressing effector memory T cells in a rat model
    Ueyama, A.
    Imura, K.
    Kasai-Yamamoto, E.
    Tai, N.
    Nagira, M.
    Shichijo, M.
    Yasui, K.
    CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2013, 38 (08) : 897 - 903
  • [33] Topical application of KPI-150, a potent inhibitor of Kv1.3 channels on effector memory T cells, demonstrates preclinical efficacy in atopic dermatitis model
    Olsen, C.
    Lustig, K.
    Iadonato, S.
    Tarcha, E.
    Guttman-Yassky, E.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2017, 137 (05) : S119 - S119
  • [34] The voltage-gated Kv1.3 K+ channel in effector memory T cells as new target for MS (vol 111, pg 1703, 2003)
    Wulff, H
    Calabresi, PA
    Allie, R
    Yun, S
    Pennington, M
    Beeton, C
    Chandy, KG
    JOURNAL OF CLINICAL INVESTIGATION, 2003, 112 (02): : 298 - 298
  • [35] Functional knockout of Kv1.3 channels suppresses effector memory phenotype acquisition in dominant negative Kv1.3-expressing human CD4+T cells
    Hu, Lina
    Whartenby, Katharine
    Allie, Rameeza
    Calabresi, Peter
    CLINICAL IMMUNOLOGY, 2007, 123 : S124 - S124
  • [36] Targeting Kv1.3 K+ channels in effector memory T cell for the therapy of autoimmune diseases.
    Beeton, C
    Wulff, H
    Pennington, MW
    Calabresi, PA
    Wang, PH
    LeeHealey, CJ
    Andrews, BS
    Chandy, KG
    ARTHRITIS AND RHEUMATISM, 2005, 52 (09): : S491 - S492
  • [37] Correolide analogs: Potential human T cell Kv1.3 potassium channel blockers.
    Lew, A
    Hamilton, MR
    Chamberlin, AR
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2000, 219 : U53 - U53
  • [38] Abnormal differentiation of memory T cells in systemic lupus erythematosus
    Fritsch, Ruth D.
    Shen, Xinglei
    Illei, Gabor G.
    Yarboro, Cheryl H.
    Prussin, Calman
    Hathcock, Karen S.
    Hodes, Richard J.
    Lipsky, Peter E.
    ARTHRITIS AND RHEUMATISM, 2006, 54 (07): : 2184 - 2197
  • [39] Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases
    Schmitz, A
    Sankaranarayanan, A
    Azam, P
    Schmidt-Lassen, K
    Homerick, D
    Hänsel, W
    Wulff, H
    MOLECULAR PHARMACOLOGY, 2005, 68 (05) : 1254 - 1270
  • [40] Targeting effector memory T cells with the small molecule Kv1.3 blocker PAP-1 suppresses allergic contact dermatitis
    Azam, Philippe
    Sankaranarayanan, Ananthakrishnan
    Homerick, Daniel
    Griffey, Stephen
    Wulff, Heike
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2007, 127 (06) : 1419 - 1429
12345